Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronized progesterone on the mammary gland, an international expert panel's recommendations are as follows: (1) estrogens combined with oral (approved) or vaginal (off-label use) micronized progesterone do not increase breast cancer risk for up to 5 years of treatment duration; (2) there is limited evidence that estrogens combined with oral micronized progesterone applied for more than 5 years are associated with an increased breast cancer risk; and (3) counseling on combined MHT should cover breast cancer riskregardless of the progestogen chosen. Yet, women should also be counseled on other modifiable and non-modifiable breast cancer risk factors in order to balance the impact of combined MHT on the breast.
Introduction
The steroid hormone progesterone (P) plays a key role in female reproduction 1 . For therapeutic reasons, micronized progesterone (MP) can be used, for example, for endometrial protection when estrogens are applied in menopausal women with an intact uterus 2 . To discuss various topics on MP, regular international expert meetings of three gynecological endocrinologists from the German-speaking countries, Austria, Germany and Switzerland, have been held since 2015 aiming to provide scientifically proven statements on MP treatment in peri-and postmenopausal women, based on a systematic literature search and discussion of the results. The impact of estrogens combined with MP on the mammary gland, especially on breast density, biopsies (benign breast tissue) and cancer risk is the second topic of this series 3 .
Material and methods
In May 2016, a systematic literature search was performed by an independent agency (gwd consult) using the databases Medline (Pubmed) and Embase. Only articles in English were included. There was no time restriction applied. For each topic (impact of MP on (1) breast biopsy, (2) breast histology and (3) breast cancer risk), individual searches were performed using multiple combinations of keywords, Meshterms and text words related to the respective topic. For the first topic, included keywords were 'progesterone', 'breast', 'density', 'treatment', 'micronized', 'mammography', 'exogenous', 'hormone', 'proliferation', 'HRT', 'bio-identical', while 'MPA', 'norethisterone', 'progestin', 'medroxyprogesterone' and 'receptor' were excluded keywords. The search yielded 60 relevant articles. For the second topic, included keywords were 'progesterone', 'histologic', 'treatment', 'breast', 'hormone', 'biopsy', 'parenchymal', 'bioidentical' and 'histology' and excluded keywords were 'progestin', 'medroxyprogesterone', 'norethisterone' and 'receptor". The search yielded 30 relevant articles. For the third topic, included keywords were 'progesterone', 'breast', 'cancer', 'risk', 'treatment', 'micronized', 'bio-identical' while excluded keywords included 'receptor' and 'progestin". The search yielded 83 relevant articles. After exclusion of duplicates, the final list of relevant articles comprised 141 out of all relevant 173 articles. After May 2016, five additional articles have been identified and included into the review [4] [5] [6] [7] [8] . The final eligibility assessment and evaluation of the studies' quality were performed by the expert group (PS, JN, LW).
respectively. In the following, the term 'progestogen' was used as an umbrella term for MP and synthetic progestins.
Breast density
Of 60 hits, only six articles were suitable for this review [9] [10] [11] [12] [13] [14] (Table 1) . Of those, four were subgroup analyses of the placebo-controlled, randomized-controlled trial (PC-RCT) Postmenopausal Estrogen/Progestin Intervention (PEPI) trial [9] [10] [11] [12] , one was a post-hoc analysis of two PC-RCTs 13 and another one a head-to-head RCT 14 . Sample size ranged from 77 14 to 571 10 postmenopausal women. Treatment duration ranged from 2 months 14 to 3 years 9 . Within the PEPI trial, four menopausal hormone therapy (MHT) regimens were compared to placebo [9] [10] [11] [12] Mammographic density was assessed either categorically, e.g. by Breast Imaging Reporting and Data System (BI-RADS) grades 9, 13, 14 , or continuously, e.g. by computer-based mammographic percent density [10] [11] [12] [13] . After 1 year of MHT within the PEPI trial, mammographic density was significantly increased by all estrogen-progestogen regimens but not by o-CEE or placebo [9] [10] [11] . There were no group differences between combined MHT regimens [9] [10] [11] . All mammographic density increases observed comprised only one category and mostly appeared during the first year of MHT use 9 . Similarly, mammographic density was significantly increased by oral estrogens combined with trimegestone 13 or MPA 14 . In contrast, mammographic density remained unchanged after treatment with oral or nasal estrogens combined with o-MP 13, 14 . Furthermore, the associations between mammographic density and new-onset breast discomfort 11 , change in serum progestogen levels or progesterone receptor genotype 12 were analyzed. Women with new-onset breast discomfort had a 3.9% increase in mammographic density regardless of MHT type 11 . Increases of serum progestogen in the highest quartile were associated with 3.5% higher mammographic density compared to increases in the lowest quartile. However, there was no indication that genetic variations in the progesterone receptor had an impact on mammographic density or modified the impact of serum progestogen levels on mammographic density 12 .
Breast biopsy
Of 30 hits, only three studies were prospective randomized intervention trials [14] [15] [16] [17] , of which one study used o-MP 14, 15 and two topical (applied directly on the breast) MP 16, 17 , respectively ( Table 2 ). The latter two trials 16, 17 were both placebo-controlled with three active comparator arms: topical MP 25 mg/day, topical E2 gel 1.5 mg/day, and the combination of both (E2 þ MP). Study duration was short and comprised 11-14 days prior to a scheduled surgery for the removal of a breast lump. The cohorts included either 33 premenopausal 16 or 40 postmenopausal women 17 . The study endpoints were similar, namely serum steroid levels (E2, P), tissue steroid concentration (E2, P), mammary epithelial mitotic index and cell proliferation marker (PCNA) expression. While serum E2 levels were significantly higher in women applying topical E2 compared to those applying MP or placebo, significant group differences for serum P levels were only found in postmenopausal 17 but not in premenopausal topical MP users 16 . Tissue E2 concentration was significantly higher in women applying topical E2 compared to those applying placebo 16, 17 or MP 17 . Tissue P concentration was significantly higher in women applying topical MP compared to placebo 16 or did not reveal any group differences 17 . Mammary epithelial mitotic index was significantly increased in those women applying topical E2 when compared to those using topical MP 16, 17 , E2 þ MP or placebo 17 . Similarly, PCNA expression was highest in topical E2 users 16, 17 but still significantly higher in women applying topical E2 þ MP compared to women applying MP 16 and placebo 17 . Both authors came to the conclusion that topical MP for up to 14 days reduced E2-induced mammary epithelial proliferation.
The impact of a 2-month systemic MHT containing MP on the mammary gland in 77 healthy postmenopausal women was investigated by one RCT yielding three publications 14, 15 . In this RCT, head-to-head comparisons were performed using two different MHT regimes containing either o-CEE at 0.625 mg/day sequentially combined with o-MPA at 5 mg/day (o-CEE þ o-seqMPA) or t-E2 gel at 1.5 mg/day sequentially combined with o-MP at 200 mg/day (t-E2 þ o-seqMP). Core needle biopsy of the upper outer quadrant of the left breast was performed at baseline and study end. Study endpoints were breast cell proliferation (Ki-67/MIB-1) and apoptosis (bcl-2) assessed by immunohistochemistry 14, 15 , single gene expression analysis assessed by reverse transcription polymerase chain reaction (rtPCR) 14 and whole genome expression analysis by microarray 14 . Assessable breast samples at both time points were available for 10% 14 to 49% 14,15 of subjects. After 2 months of treatment, breast cell proliferation and Ki-67 gene expression were significantly increased by o-CEE þ o-MPA but not by t-E2 þ o-MP 14, 15 . In contrast, breast cell apoptosis and bcl-2 gene expression were either decreased by t-E2 þ o-MP or did not reveal group differences 14, 15 . Induction of progesterone receptor B expression was slightly but not significantly lower after t-E2 þ o-MP than o-CEE þ o-MPA treatment 14 . Microarray analysis revealed an altered gene expression profile (fold change !1.5) for 2500 genes within the o-CEE þ o-MPA arm and 300 genes within the t-E2 þ o-MP arm 14 . A total of 225 genes were involved in mammary tumor development of which 198 were attributable to o-CEE þ o-MPA and 34 to t-E2 þ o-MP. The different aspects of the study came to the conclusion that, in comparison to 'conventional' MHT, transdermal E2 combined with oral MP induced less proliferation and adverse expression of important genes regulating proliferation, apoptosis and tumor inclination in vivo.
Breast cancer risk
Breast cancer risk in respect to MHT containing MP was assessed by two systematic reviews and meta-analysis 4,7 , one retrospective cohort study 18 , two prospective cohort studies (the Etude Epid emiologique de femmes e la Mutuelle G en erale de l'Education Nationale (E3N), and Menopause: Risk of breast cancer, morbidity and prevalence (MISSION)) 8,19-21,23,24 , one case-control study (CECILE, a population-based case-control study in Cote d'Or and Ille-et-Vilaine) 25 and two PC-RCT (Kronos Early Estrogen Prevention Study (KEEPS) 22 , and Early versus Late Intervention Trial with Estradiol (ELITE) 5 ) ( Table 3 ). The first meta-analysis 7 included two cohort studies 8, 24 and reported that breast cancer risk was lower for estrogens combined with MP than with synthetic progestins (relative risk (RR) 0.67; 95% confidence interval (CI) 0.55-0.81). Mean MHT duration was 7.0 years 24 and 8.3 years 8 , respectively. According to the second metaanalysis covering 14 trials, breast cancer risk was increased when estrogens were combined with MPA, norethisterone (NET) or levonorgestrel (LNG) but not when combined with dydrogesterone (DYD) or MP 4 , respectively. However, the duration of MHT use was not considered. Except for the two US-American PC-RCTs, all other studies were performed in France. The primary endpoints were breast cancer risk 8, [18] [19] [20] [21] [23] [24] [25] or changes in carotid artery intima-media thickness 5, 22 . In the latter, breast cancer was assessed as a serious adverse event 5, 22 . The sample size ranged from 643 5 to 80 391 23 postmenopausal women, and mean follow-up from 4.0 22 to 11.2 21 years. At study entry, women were in their fifties in all 5,18-20,22-24 but two studies 5, 8 that also recruited women during late postmenopause. Only CECILE did not report on participants' age 25 . Information on MHT use was obtained from medical records 8, 18 , self-administered questionnaires at baseline 26 and then every 2 years [19] [20] [21] 23, 24 , in-person interviews 25 , and scheduled visits at 2-month 5 or 12-month 22 intervals. Mean duration of MHT use ranged from 2.8 years 19 to !10 years 18 . Adherence to medication was high in KEEPS (>94%) 22 and ELITE (98%) 5 but not reported in the other studies included.
Both PC-RCTs, KEEPS 22 and ELITE 5 used a sequentially combined MHT. In KEEPS, o-CEE at 0.45 mg/day or t-E2 patch at 50 mg/day was combined with o-MP 200 mg/day on days 1-12 of each month (o-CEE þ o-seqMP, t-E2 þ o-seqMP) 22 . In ELITE, o-E2 at 1 mg/day was combined with vaginal MP at 45 mg/day (4% gel) on 10 days during each 30-day cycle (o-E2 þ vag-seqMP) 5 . The observational cohort and case-control studies differentiated between progestogen types such as MP 8, [18] [19] [20] [21] [23] [24] [25] DYD 18, 20, 21, 23, 24 and synthetic progestins (progesterone-and testosterone derivatives) 8, 18, 19, 21, [23] [24] [25] but not between estrogen types, MHT dosages and MHT regimen (sequentially or continuously combined MHT). The definition of current and past MHT use differed between studies. For some, current MHT use corresponded to systemic estrogen therapy for !1 year [18] [19] [20] 24 . For others, current systemic MHT also comprised women that had stopped MHT use 1 year 25 or even 5 years 8 before the reference date, which in contrast was defined as past use in another study 21 . One study grouped current and past MHT use together 23 .
The first study to report on the impact of different progestogen types within combined MHT on breast cancer risk did not find a significant difference between combined MHT use and non-use (adjusted RR 1.10; 95% CI 0.73-1.66) 18 . This finding was not altered when differentiating between time since last MHT use (<5 years vs. !5 years) and duration of MHT use (<5 years vs. ! 5 years). Unfortunately, subgroup analysis for progestogen types was not performed. However, the majority of combined MHT contained MP (58%) or DYD (10%) and only <3% MPA. The MISSION trial did not find a significant difference for breast cancer risk when comparing MHT users with non-users (non-adjusted RR 0.91; 95% CI 0.45-1.86) 8 . Similarly, breast cancer risk in MHT users did not differ between MHT types and duration of use ( 5 years vs. >5 years). In contrast, when compared to MHT non-use, the first E3N report from 2005 found a significant increased breast cancer risk for any combined MHT use (multivariate adjusted RR 1.3; 95% CI 1.1-1.5) 19 . Breast cancer risk was not altered by duration of MHT use (<2 years vs. 2-4 years vs. !4 years; p for trend ¼ 0.7). However, when differentiating for progestogen type, estrogens combined with oral MP were not associated with an increased breast cancer risk (multivariate adjusted RR 0.9; 95% CI 0.7-1.2), while estrogens combined with synthetic progestins were (multivariate adjusted RR 1.4; 95% CI 1.2-1.7). Duration of MHT use (<2 years vs. 2-4 years vs. !4 years) only had a slight impact when oral estrogens were combined with synthetic progestins (p for trend ¼ 0.07) but not when combined with MP (p for trend ¼ 0.9). Similarly, the second E3N report published in 2008 did not find an increased breast cancer risk for combined MHT containing either MP or DYD regardless of MHT duration (<2 years vs. 2-<4 years vs. !4-<6 years vs. !6 years), although a significant time trend was observed in women using estrogens combined with MP (p for trend ¼ 0.04) 24 . In addition, combined MHT containing MP was not found to be associated with any breast cancer subtype 23 . These findings were supported by CECILE 25 . However, the numbers of cases and controls were very small in subgroups and the authors did not differentiate between invasive and in situ breast cancer. In contrast, the third E3N report from 2014 found a significant increased breast cancer risk for mean 6.1 years of use of combined MHT containing MP or DYD (multivariate adjusted RR 1.22; 95% CI 1. 11-1.35) . When differentiating between short-term ( 5 years) and long-term use (>5 years), a significant increased breast cancer risk was only found for long-term use (multivariate adjusted RR 1.31; 95% CI 1.15-1.48). In comparison, use of combined MHT containing synthetic progestogens for more than 5 years was associated with an increased breast cancer risk (multivariate adjusted RR 1.98; 95% CI 1.73-2.26). Importantly, after stopping MHT containing MP or DYD after >5 years of use, breast cancer risk dissolved immediately (3 months to 5 years since last use: multivariate adjusted RR 1.15; 95% CI 0.93-1.42). In contrast, breast cancer risk was still elevated even 5-10 years after stopping MHT containing synthetic progestins when use was at least 5 years (multivariate adjusted RR 1.34; 95% CI 1.04-1.73). The time gap between menopause and MHT initiation did not have an impact on breast cancer risk in women using estrogens combined with MP 20,21 . In the two PC-RCTs, breast cancer was newly diagnosed in eight women in KEEPS 22 (n ¼ 3 o-CEE, n ¼ 3 t-E2, n ¼ 2 placebo), and in 18 women in ELITE 5 (n ¼ 10 o-E2, n ¼ 8 placebo), respectively. The difference between MHT and placebo groups was not significant in both studies.
Discussion
Current international guidelines on MHT recommend to combine a progestogen when using estrogen therapy in periand postmenopausal women with an intact uterus for endometrial protection 2,27-29 . However, long-term combined estrogen-progestogen therapy has been shown to be associated with an increased breast cancer risk. During the last years, the debate about (compounded) bioidentical hormones has increased tremendously [30] [31] [32] . Specifically, the question has been raised whether bioidentical hormone therapy including MP has a different or even beneficial impact on the mammary gland. Internationally, systemic MP is available at different dosages and routes of application. Also, indication and approval by regulatory authorities may differ from country to country. In Europe, systemic MP is available as a capsule (100 mg, 200 mg) for vaginal or oral application or as a vaginal gel (8% corresponding to 90 mg).
Our systematic review on the impact of estrogens combined with MP on the postmenopausal mammary gland showed that (1) mammographic density may either increase or remain unchanged, (2) proliferation induction was less pronounced compared to 'conventional' MHT, and (3) breast cancer risk was not affected for up to 5 years of treatment. However, (4) estrogens combined with MP or dydrogesterone were associated with a slight but significant increase in breast cancer risk after an average of 6 years of treatment duration.
Breast density is a mammographic finding based on differing proportions of fat, connective and epithelial tissue. Mammographic density can be assessed either by the BI-RADS classification (almost entirely fatty, scattered areas of fibroglandular density, heterogeneously dense, extremely dense) 33 or by more objective, but not widely implemented computer-based breast density assessments [34] [35] [36] . Mammographically dense breast tissue both decreases the sensitivity of mammograms and increases breast cancer risk 37 but not breast cancer mortality 38 . There are multiple factors contributing to mammographic density such as age, genetics, body habitus, parity, and MHT use. Our systematic review revealed contradicting results for MHT containing MP, with two studies showing no change 13, 14 and three substudies showing a significant increase in mammographic density [9] [10] [11] . The latter are in line with another longitudinal study showing that the age-related change from dense to fatty breast tissue was slowed down more in women taking combined MHT than in those taking estrogen alone 39 . The differing results may also be due to the method itself and differences between the US-American 4-6 and European 13, 14 cohorts. US-American women were in their late fifties, overweight and had mostly used MHT before [4] [5] [6] , while European women were younger at least in one substudy 13 and had a normal body mass index 8, 9 . Baseline mammographic density was reported by all but one study 14 . Most women (approximately 60%) fell into the BI-RADS categories 1 and 2 [9] [10] [11] 13 . However, mammographic density interpretation is subjective to some degree as moderate interobserver and intraobserver variabilities, especially between the BI-RADS categories of heterogeneously dense and scattered areas of fibroglandular density, have been reported [40] [41] [42] . Accordingly, a striking but non-significant interobserver variability was reported by one study 9 .
Due to heterogeneous study designs, reports on the impact of estrogens combined with MP on breast tissue were not comparable. Outcome markers differed, ranging from tissue sex steroid concentrations, immunohistochemistry, rtPCR to microarray gene expression analysis. Study duration was short and 2 months at maximum. Furthermore, two studies used topical MP 16, 17 which is not thought to have a systemic impact 43 . The observed differences in tissue E2 and P concentrations may be due to pharmacological interference and different reproductive stages. Thus, there is only some weak evidence from breast biopsies in healthy women showing that estrogens combined with oral MP are more 'breast friendly' than estrogens combined with oral MPA, a finding supported by studies in non-human primates 44, 45 .
In respect to breast cancer risk, all studies confirmed that estrogens combined with MP did not increase breast cancer risk when treatment duration was 5 years or less. The only two studies assessing breast cancer risk in women using MHT containing MP for more than 5 years are the prospective cohort studies E3N and MISSION. Yet, compliance, dosage and route of application of MP were not exactly known. In addition, the E3N report from 2014 did not differentiate between MP and dydrogesterone. Another limitation of E3N was the high rates of MHT changes over time: of those who ever used estrogens combined with MP or dydrogesterone, 57% also used estrogens combined with synthetic progestogens 21 . The majority of studies used oral MP, which is the approved way of application for MHT. Thus, breast safety data on vaginal MP is scarce 5 or completely lacking for transdermal MP. Despite the limited evidence, women should be counseled that, if using combined MHT for more than 5 years, the risk of being diagnosed with breast cancer increasesregardless of the progestogen type chosen. However, in order to balance the impact of non-modifiable (e.g. genetics, breast density, parity) and modifiable breast cancer risk factors (e.g. alcohol, smoking, overweight/obesity, physical inactivity, MHT), women should also be counseled that the possible increased breast cancer risk with combined MHT is small (<1 per 1000 women per year of use) and lower than the increased risks associated with common lifestyle factors such as reduced physical activity, obesity and alcohol consumption 46 .
Conclusion
Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. Based on a systematic literature review on the impact of micronized progesterone on the mammary gland, an international expert panel's recommendations on MHT containing micronized progesterone are as follows: (1) estrogens combined with oral (approved) or vaginal (off-label use) micronized progesterone do not increase breast cancer risk for up to 5 years of treatment duration; (2) there is limited evidence that estrogens combined with oral micronized progesterone applied for more than 5 years are associated with an increased breast cancer risk; and (3) counseling on combined MHT should cover breast cancer riskregardless of the progestogen chosen. Yet, women should also be counseled on other modifiable and non-modifiable breast cancer risk factors in order to balance the impact of combined MHT on the breast.
